blue curve graphic

Creating Exceptional Medicines
with Structure and ReSOLVE™

Our lead program VENT-02, a brain-penetrant NLRP3 inhibitor, is in a Phase 2a trial for Parkinson’s disease. Our second lead program – VENT-03, a first-in-class cGAS inhibitor – is expected to enter Phase 2 development for lupus in 2025.

We are a clinical-stage biopharmaceutical company leveraging our machine learning-enabled ReSOLVE™ platform to advance a pipeline of novel medicines in immunology, inflammation, and neurology.

Pipeline » Platform »

Join a team working to reveal the unmarked paths to new medicines.

Central to our ethos is the belief that our employees should be empowered to solve complex problems with bold and innovative solutions.

If you’re up for a journey with an exceptional team pursuing exciting science, please check out our job openings below. We’re always on the lookout for talented people – and we are growing!

Careers »